Home / Health / GLP-1 Drugs Linked to Rare Vision Loss?
GLP-1 Drugs Linked to Rare Vision Loss?
22 Sep
Summary
- Lawsuits claim GLP-1 drug makers didn't warn of vision loss risk.
- No study has definitively proven GLP-1 drugs cause vision loss.
- Other countries require warnings about potential vision risks.
Dozens of personal injury lawsuits have been filed against manufacturers of GLP-1 drugs, including Ozempic, Wegovy, and Mounjaro. Plaintiffs allege they were not adequately informed about the risk of nonarteritic anterior ischemic optic neuropathy (NAION), a rare form of sudden vision loss.
While a potential link between these popular medications and NAION has been under investigation since a 2024 report, no conclusive study has proven causation. Manufacturers assert the lawsuits are without merit and are actively defending against them.
NAION, characterized by acute, painless vision loss, is the most common optic neuropathy in individuals over 50. Diabetes, low blood pressure, and small optic nerve cups are known risk factors, independent of GLP-1 use.
Regulatory bodies like the European Medicines Agency and Australia's Therapeutic Goods Administration have prompted warnings on these drugs regarding the rare risk of NAION. The FDA continues to monitor safety signals.
Experts emphasize that while some studies suggest a potential association, the risk appears rare and causation remains unproven. The significant benefits of GLP-1s for diabetes, obesity, and cardiovascular health are well-established.
